MX378264B - Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. - Google Patents
Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.Info
- Publication number
- MX378264B MX378264B MX2018001499A MX2018001499A MX378264B MX 378264 B MX378264 B MX 378264B MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 378264 B MX378264 B MX 378264B
- Authority
- MX
- Mexico
- Prior art keywords
- liquid polymer
- drugs
- delivery system
- polymer delivery
- extended administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200198P | 2015-08-03 | 2015-08-03 | |
| US201662275407P | 2016-01-06 | 2016-01-06 | |
| PCT/US2016/045334 WO2017024027A1 (en) | 2015-08-03 | 2016-08-03 | Liquid polymer delivery system for extended administration of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001499A MX2018001499A (es) | 2018-08-01 |
| MX378264B true MX378264B (es) | 2025-03-10 |
Family
ID=56684769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001499A MX378264B (es) | 2015-08-03 | 2016-08-03 | Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10786515B2 (https=) |
| EP (2) | EP3804698B1 (https=) |
| JP (1) | JP6949820B2 (https=) |
| KR (1) | KR102696721B1 (https=) |
| CN (1) | CN107920988B (https=) |
| AU (1) | AU2016302252B2 (https=) |
| BR (1) | BR112018002414B1 (https=) |
| CA (1) | CA2994704A1 (https=) |
| DK (1) | DK3331495T3 (https=) |
| EA (1) | EA036951B1 (https=) |
| ES (2) | ES2836805T3 (https=) |
| HR (1) | HRP20201991T1 (https=) |
| HU (1) | HUE052832T2 (https=) |
| IL (1) | IL257221B (https=) |
| MX (1) | MX378264B (https=) |
| PT (1) | PT3331495T (https=) |
| TW (1) | TWI718168B (https=) |
| WO (1) | WO2017024027A1 (https=) |
| ZA (1) | ZA201800591B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084460A2 (en) | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| JP6949820B2 (ja) | 2015-08-03 | 2021-10-13 | トルマー インターナショナル リミテッド | 薬物の持続投与のための液体ポリマー送達システム |
| WO2019232283A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| KR102051808B1 (ko) | 2018-07-23 | 2019-12-04 | 주식회사 종근당 | 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물 |
| TW202027725A (zh) | 2018-09-25 | 2020-08-01 | 愛爾蘭商托爾瑪國際有限公司 | 供藥物之延長投予之液體聚合物輸送系統 |
| CN109966557A (zh) * | 2018-12-05 | 2019-07-05 | 博志生物科技有限公司 | 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用 |
| HUE069400T2 (hu) * | 2019-09-30 | 2025-03-28 | Tolmar International Ltd | Folyékony polimer készítmények és rendszerek peptidek mint hatóanyagok nyújtott leadására |
| CN110946826B (zh) * | 2019-12-12 | 2022-02-22 | 烟台大学 | 一种利奥西呱口服制剂及其制备方法 |
| EP4221688A1 (en) * | 2020-09-30 | 2023-08-09 | Tolmar International Limited | Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients |
| WO2024117740A1 (ko) * | 2022-11-28 | 2024-06-06 | 동국제약 주식회사 | 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법 |
| WO2024131788A1 (zh) * | 2022-12-23 | 2024-06-27 | 长春金赛药业有限责任公司 | 一种GnRH拮抗剂可注射组合物及其制备方法和应用 |
| EP4661840A2 (en) * | 2023-02-10 | 2025-12-17 | Tolmar International Limited | Degarelix polymeric formulations |
| JP2026505354A (ja) * | 2023-02-10 | 2026-02-13 | トルマー インターナショナル リミテッド | デガレリクスの有機溶媒製剤 |
| CN119074641A (zh) * | 2024-09-02 | 2024-12-06 | 万邦德制药集团有限公司 | 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US6197320B1 (en) * | 1994-03-11 | 2001-03-06 | Shalaby W. Shalaby | Absorbable E-caprolactone polymers and medical devices |
| US5668288A (en) * | 1996-04-16 | 1997-09-16 | Depuy Orthopaedics, Inc. | Polyester ionomers for implant fabrication |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| EP1334990A1 (en) | 2002-02-06 | 2003-08-13 | Polyganics B.V. | DL-Lactide-epsilon-caprolactone copolymers |
| US20120225033A1 (en) | 2010-11-24 | 2012-09-06 | Durect Corporation | Biodegradable Drug Delivery Composition |
| DK1635875T3 (da) | 2003-06-26 | 2009-01-12 | Psivida Inc | In-situ-geldannende lægemiddeladministrationssystem |
| JP2008524235A (ja) * | 2004-12-15 | 2008-07-10 | キューエルティー ユーエスエー，インコーポレイテッド． | オクトレオチド化合物の徐放性送達処方物 |
| CA2604943C (en) | 2005-04-15 | 2013-09-17 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| CA2618404A1 (en) | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
| US20070299043A1 (en) | 2005-10-03 | 2007-12-27 | Hunter William L | Anti-scarring drug combinations and use thereof |
| WO2007084460A2 (en) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| US7740877B2 (en) | 2006-04-07 | 2010-06-22 | University Of Utah Research Foundation | Aliphatically modified biodegradable block copolymers as thermogelling polymers |
| CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
| US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US8946277B2 (en) * | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
| RU2504360C2 (ru) | 2008-08-12 | 2014-01-20 | Новартис Аг | Фармацевтические композиции |
| US8541360B2 (en) | 2008-11-19 | 2013-09-24 | Ben Venue Laboratories, Inc. | Parenteral formulations comprising sugar-based esters and ethers |
| WO2010085608A1 (en) * | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same |
| AP3138A (en) | 2009-04-24 | 2015-02-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
| GB2513267B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| WO2012005594A2 (en) | 2010-07-09 | 2012-01-12 | Innocore Technologies B.V. | Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides |
| KR20130100345A (ko) * | 2010-11-04 | 2013-09-10 | 신닛테츠 수미킨 가가쿠 가부시키가이샤 | 하드코트층 부착 폴리카보네이트 |
| US20140309202A1 (en) | 2010-11-30 | 2014-10-16 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| DK2691079T3 (da) | 2011-03-31 | 2020-09-28 | Ingell Tech Holding B V | Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning |
| HRP20192276T1 (hr) * | 2011-06-10 | 2020-05-15 | Ramscor, Inc. | Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme |
| CA2852386C (en) * | 2011-10-17 | 2019-05-21 | Poly-Med, Inc. | Absorbable in situ gel-forming system, method of making and use thereof |
| WO2015165976A1 (en) | 2014-05-01 | 2015-11-05 | Ingell Technologies Holding B.V. | Liquid triblock copolymer |
| KR101686986B1 (ko) | 2014-07-28 | 2016-12-16 | 에스케이케미칼주식회사 | 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| JP6949820B2 (ja) | 2015-08-03 | 2021-10-13 | トルマー インターナショナル リミテッド | 薬物の持続投与のための液体ポリマー送達システム |
| US11752099B2 (en) | 2017-03-27 | 2023-09-12 | W. L. Gore & Associates, Inc. | Injectable and biodegradable polymer formulations for controlled release of bioactive agents |
-
2016
- 2016-08-03 JP JP2018506344A patent/JP6949820B2/ja active Active
- 2016-08-03 HR HRP20201991TT patent/HRP20201991T1/hr unknown
- 2016-08-03 MX MX2018001499A patent/MX378264B/es unknown
- 2016-08-03 EP EP20205445.8A patent/EP3804698B1/en active Active
- 2016-08-03 EA EA201890436A patent/EA036951B1/ru unknown
- 2016-08-03 CN CN201680045838.XA patent/CN107920988B/zh active Active
- 2016-08-03 EP EP16751437.1A patent/EP3331495B1/en active Active
- 2016-08-03 CA CA2994704A patent/CA2994704A1/en active Pending
- 2016-08-03 TW TW105124656A patent/TWI718168B/zh active
- 2016-08-03 PT PT167514371T patent/PT3331495T/pt unknown
- 2016-08-03 ES ES16751437T patent/ES2836805T3/es active Active
- 2016-08-03 KR KR1020187005376A patent/KR102696721B1/ko active Active
- 2016-08-03 WO PCT/US2016/045334 patent/WO2017024027A1/en not_active Ceased
- 2016-08-03 US US15/749,030 patent/US10786515B2/en active Active
- 2016-08-03 ES ES20205445T patent/ES2975519T3/es active Active
- 2016-08-03 DK DK16751437.1T patent/DK3331495T3/da active
- 2016-08-03 BR BR112018002414-7A patent/BR112018002414B1/pt active IP Right Grant
- 2016-08-03 AU AU2016302252A patent/AU2016302252B2/en active Active
- 2016-08-03 HU HUE16751437A patent/HUE052832T2/hu unknown
-
2018
- 2018-01-29 IL IL257221A patent/IL257221B/en unknown
- 2018-01-29 ZA ZA2018/00591A patent/ZA201800591B/en unknown
-
2020
- 2020-08-17 US US16/995,020 patent/US11779589B2/en active Active
-
2023
- 2023-08-09 US US18/446,687 patent/US12447158B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378264B (es) | Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. | |
| WO2017091749A8 (en) | Shape changing drug delivery devices and methods | |
| MX2021001118A (es) | Composiciones que comprenden fibras obtenidas electrohidrodinamicamente para la administracion de dosificaciones especificas de una sustancia activa a piel o mucosa. | |
| WO2012035429A3 (en) | Remotely controlled drug delivery systems | |
| MX352907B (es) | Composiciones de un poliortoéster y un solvente aprótico. | |
| MX2015011393A (es) | Poli(beta-amino esteres) modificados para suministro de farmaco. | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| MX2017006653A (es) | Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión. | |
| MX2019003804A (es) | Dispositivos implantables para suministro de medicamento con liberacion de descarga reducida. | |
| WO2011112229A3 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
| EA033537B1 (ru) | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью | |
| WO2015095624A3 (en) | Drug mixing and delivery system and method | |
| MD20160079A2 (ro) | Sistem de livrare a medicamentului | |
| MX2018002627A (es) | Metodo de cristalizacion y biodisponibilidad. | |
| WO2011112996A3 (en) | Injectable drug delivery system | |
| WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| AR116501A1 (es) | Sistema de suministro de polímero líquido para administración extendida de drogas | |
| MX371139B (es) | Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada. | |
| PE20160850A1 (es) | Sistema multiparticulado para administrar drogas | |
| MX2016001607A (es) | Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas. | |
| PE20160534A1 (es) | Sistema de administracion intrauterina | |
| MX2016015261A (es) | Dispersion solida de allisartan isoproxilo y su composicion. | |
| EP3801703A4 (en) | Tissue integrated drug delivery system | |
| CR20140358A (es) | Sistema para la administración de fármacos | |
| WO2016036823A3 (en) | Self-assembling drug delivery vehicles with ionically cross-linked drugs |